Stock listing
NASDAQ:ALMS Alumis Inc. Stock
Home listing (NASDAQ) of Alumis Inc.
Follow Alumis Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:ALMS
$3.96 USD -0.43 (-9.9%)
Close on Nov 20, 2026
- Day range
- $3.94 – $4.36 USDNov 20, 2026
- Volume
- 1.79M sharesNov 20, 2026
- Market cap
- $512.6M USDAt the close on Nov 20, 2026 · price × 129.4M shares outstanding
- 52-week range
- $3.94 – $31.35 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $24.34M USDMedian day 2.13M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:ALMS · Home | $3.96 USD | -0.435 (-9.9%) | 1,794,304 | $4.235 | $4.36 | $3.935 | $4.395 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ALMS · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $3.96 | -0.435 | -9.9% | $4.235 | $4.36 | $3.935 | 1,794,304 | |
| $4.395 | -0.445 | -9.2% | $4.92 | $4.95 | $4.35 | 2,009,295 | |
| $4.84 | -0.30 | -5.8% | $5.05 | $5.126 | $4.701 | 1,860,719 | |
| $5.14 | -0.46 | -8.2% | $5.59 | $5.80 | $5.00 | 2,200,177 | |
| $5.60 | -0.53 | -8.6% | $6.035 | $6.10 | $5.52 | 1,492,039 | |
| $6.13 | -0.49 | -7.4% | $6.50 | $6.61 | $6.13 | 1,862,859 | |
| $6.62 | +0.22 | +3.4% | $6.47 | $6.72 | $6.425 | 1,282,890 | |
| $6.40 | -0.15 | -2.3% | $6.56 | $6.67 | $6.275 | 1,542,120 | |
| $6.55 | +0.52 | +8.6% | $6.14 | $6.60 | $5.99 | 2,405,490 | |
| $6.03 | +0.18 | +3.1% | $5.88 | $6.08 | $5.82 | 1,279,001 | |
| $5.85 | -0.70 | -10.7% | $6.51 | $6.526 | $5.75 | 1,945,991 | |
| $6.55 | +0.05 | +0.8% | $6.575 | $6.70 | $6.34 | 1,289,994 | |
| $6.50 | +0.12 | +1.9% | $6.41 | $6.61 | $6.215 | 2,562,452 | |
| $6.38 | -0.35 | -5.2% | $6.81 | $6.81 | $6.255 | 1,430,090 | |
| $6.73 | -0.16 | -2.3% | $6.84 | $6.92 | $6.46 | 2,236,875 | |
| $6.89 | -0.24 | -3.4% | $7.19 | $7.245 | $6.68 | 2,743,111 | |
| $7.13 | +0.49 | +7.4% | $6.60 | $7.18 | $6.59 | 2,431,728 | |
| $6.64 | +0.13 | +2.0% | $6.51 | $6.69 | $6.30 | 3,258,301 | |
| $6.51 | -0.27 | -4.0% | $6.76 | $6.825 | $6.375 | 1,119,816 | |
| $6.78 | -0.04 | -0.6% | $6.68 | $6.82 | $6.48 | 1,230,171 | |
| $6.82 | +0.01 | +0.1% | $6.72 | $6.945 | $6.655 | 1,503,555 | |
| $6.81 | +0.11 | +1.6% | $6.75 | $6.945 | $6.66 | 1,230,135 | |
| $6.70 | +0.36 | +5.7% | $6.33 | $6.725 | $6.25 | 1,534,294 | |
| $6.34 | +0.22 | +3.6% | $6.12 | $6.43 | $6.10 | 1,483,621 | |
| $6.12 | -0.19 | -3.0% | $6.31 | $6.31 | $6.01 | 2,496,575 | |
| $6.31 | +0.25 | +4.1% | $6.11 | $6.50 | $6.08 | 2,786,515 | |
| $6.06 | -0.50 | -7.6% | $6.47 | $6.55 | $6.015 | 2,298,082 | |
| $6.56 | -0.50 | -7.1% | $7.01 | $7.01 | $6.535 | 1,899,400 | |
| $7.06 | -0.10 | -1.4% | $7.13 | $7.31 | $6.97 | 1,601,100 | |
| $7.16 | +0.19 | +2.7% | $7.04 | $7.285 | $6.90 | 1,371,100 | |
| $6.97 | +0.20 | +3.0% | $6.66 | $7.02 | $6.61 | 2,853,100 | |
| $6.77 | -0.16 | -2.3% | $6.82 | $6.95 | $6.71 | 2,167,200 | |
| $6.93 | +0.09 | +1.3% | $6.89 | $6.95 | $6.64 | 1,745,500 | |
| $6.84 | -0.01 | -0.1% | $6.99 | $7.17 | $6.78 | 3,869,200 | |
| $6.85 | -0.36 | -5.0% | $7.28 | $7.31 | $6.635 | 2,624,700 | |
| $7.21 | -0.18 | -2.4% | $7.40 | $7.48 | $7.15 | 2,130,400 | |
| $7.39 | +0.10 | +1.4% | $7.35 | $7.555 | $7.15 | 1,402,000 | |
| $7.29 | +0.13 | +1.8% | $7.16 | $7.41 | $7.13 | 1,667,900 | |
| $7.16 | +0.06 | +0.8% | $7.10 | $7.22 | $6.83 | 2,244,700 | |
| $7.10 | -0.19 | -2.6% | $7.33 | $7.38 | $7.035 | 1,718,100 | |
| $7.29 | -0.15 | -2.0% | $7.43 | $7.45 | $7.22 | 2,604,400 | |
| $7.44 | -0.67 | -8.3% | $8.03 | $8.075 | $7.31 | 2,693,500 | |
| $8.11 | +0.21 | +2.7% | $8.01 | $8.14 | $7.67 | 2,523,100 | |
| $7.90 | +0.13 | +1.7% | $7.82 | $7.92 | $7.56 | 2,431,300 | |
| $7.77 | -0.05 | -0.6% | $7.83 | $7.905 | $7.535 | 6,384,000 | |
| $7.82 | -0.12 | -1.5% | $8.03 | $8.11 | $7.755 | 3,514,800 | |
| $7.94 | -0.46 | -5.5% | $8.45 | $8.47 | $7.79 | 4,800,700 | |
| $8.40 | -0.82 | -8.9% | $9.18 | $9.20 | $8.31 | 4,003,700 | |
| $9.22 | +0.04 | +0.4% | $9.25 | $9.356 | $9.02 | 4,027,100 | |
| $9.18 | -0.72 | -7.3% | $9.99 | $10.11 | $9.14 | 3,434,300 | |
| $9.90 | +0.10 | +1.0% | $10.55 | $10.55 | $9.65 | 4,731,200 | |
| $9.80 | -0.78 | -7.4% | $10.49 | $10.67 | $9.77 | 3,874,800 | |
| $10.58 | -0.52 | -4.7% | $11.05 | $11.22 | $10.25 | 4,490,300 | |
| $11.10 | -0.26 | -2.3% | $11.23 | $11.60 | $11.01 | 3,077,100 | |
| $11.36 | +1.01 | +9.8% | $10.38 | $11.92 | $10.31 | 7,547,600 | |
| $10.35 | +0.88 | +9.3% | $10.16 | $10.77 | $9.95 | 10,377,000 | |
| $9.47 | -12.34 | -56.6% | $9.93 | $11.06 | $8.75 | 28,399,000 | |
| $21.81 | -0.57 | -2.5% | $22.29 | $22.55 | $21.28 | 1,372,900 | |
| $22.38 | -0.83 | -3.6% | $22.83 | $23.28 | $22.35 | 655,000 | |
| $23.21 | -0.41 | -1.7% | $23.49 | $24.13 | $23.08 | 503,600 | |
| $23.62 | -0.34 | -1.4% | $24.14 | $24.14 | $23.16 | 642,500 | |
| $23.96 | +0.93 | +4.0% | $23.52 | $24.04 | $23.24 | 587,300 | |
| $23.03 | -1.14 | -4.7% | $23.69 | $23.74 | $22.43 | 850,600 | |
| $24.17 | +1.31 | +5.7% | $22.98 | $24.70 | $22.21 | 934,200 | |
| $22.86 | -1.13 | -4.7% | $23.76 | $23.93 | $22.03 | 949,300 |
- Ticker
- NASDAQ:ALMS
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 12, 2026
Alumis Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates
Latest deck · Sep 1, 2026
Technical Presentation (September 2026)
Technical · 20 slides
Latest news
Alumis Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates
Nov 12, 2026
Closed $5.60 (-8.6%) on Nov 13, 2026
Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures
Oct 9, 2026
Closed $7.16 (+2.7%) on Oct 9, 2026
Alumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements
Aug 14, 2026
Closed $25.31 (+3.7%) on Aug 14, 2026
Envudeucitinib Long-term Data Positioned to Set a New Standard for Plaque Psoriasis Treatment, Delivering Highest Reported PASI 100 Skin Clearance Among Oral Therapies
Aug 10, 2026
Closed $25.37 (-7.8%) on Aug 11, 2026
Alumis Reports First Quarter 2026 Financial Results and Highlights Recent Achievements
May 14, 2026
Closed $24.63 (-0.9%) on May 14, 2026
Alumis’ Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis
Mar 28, 2026
Closed $20.21 (-18.5%) on Mar 30, 2026
Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements
Mar 19, 2026
Closed $25.38 (-0.2%) on Mar 19, 2026
Alumis Announces Late-Breaker Oral Presentation of Phase 3 Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis at 2026 American Academy of Dermatology Annual Meeting
Mar 18, 2026
Closed $25.42 (-3.0%) on Mar 18, 2026
Alumis to Present at the Leerink Partners Global Healthcare Conference
Mar 2, 2026
Closed $29.72 (+0.1%) on Mar 2, 2026
Alumis to Participate in Upcoming February Investor Conferences
Feb 5, 2026
Closed $26.34 (0.0%) on Feb 5, 2026
Alumis Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 16 in the last 12 months · 50 in all · newest Nov 12, 2026 · oldest 2024
- Decks
- 18 decks · latest Sep 1, 2026
Where Alumis Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:ALMS · Home listing · This page | NASDAQ | United States | USD |
| BOATS:ALMS | BOATS | United States | USD |
Valuation
EV/sales 16.1× against a median of 23.3×: 3rd lowest of 6 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $116.5M USD
- P/E
- Loss
- EV/sales
- 16.1×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 1.4×
- Gross margin
- 88.0%
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- 0.1×
- Beta vs S&P 500
- 1.58
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Alumis Inc. · NASDAQ:ALMS | US$512.6M | US$116.5M | n/a | 16.1× | n/a | 1.4× | n/a | 0.1× | 1.58 |
| Surrozen, Inc. · NASDAQ:SRZN | US$542.5M | US$448.0M | n/a | 42.5× | n/a | n/a | n/a | n/a | 1.64 |
| Climb Bio, Inc. · NASDAQ:CLYM | US$539.8M | US$335.4M | n/a | n/a | n/a | 2.4× | n/a | 0.0× | 1.44 |
| Abbisko Cayman Limited · HKEX:2256 | US$518.9M | US$228.7M | n/a | n/a | n/a | 1.6× | n/a | 0.2× | n/a |
| Electra Therapeutics, Inc. · NASDAQ:ETRA | US$509.8M | US$107.3M | n/a | n/a | n/a | 1.3× | n/a | 0.0× | n/a |
| Wave Life Sciences Ltd. · NASDAQ:WVE | US$504.9M | US$74.16M | n/a | 1.1× | n/a | 1.3× | −296.9% | 0.0× | 1.70 |
| Adlai Nortye Group Ltd. · NASDAQ:ANL | US$502.2M | US$297.0M | n/a | 59.4× | n/a | 2.3× | −710.6% | 0.1× | 1.96 |
| Steminent Biotherapeutics, Inc. · TPEX:7729 | US$497.0M | US$470.5M | n/a | n/a | n/a | 16.2× | n/a | 0.0× | n/a |
| Xuanzhu Biopharmaceutical Co., Ltd. Class H · HKEX:2575 | US$495.2M | US$407.3M | n/a | 23.3× | n/a | 2.2× | −200.8% | 0.0× | n/a |
| TenNor Therapeutics Suzhou Ltd. Class H · HKEX:6872 | US$489.2M | US$391.8M | n/a | n/a | n/a | 5.0× | n/a | 0.1× | n/a |
| Crescent Biopharma, Inc. · NASDAQ:CBIO | US$482.9M | US$196.0M | n/a | 13.1× | n/a | 1.8× | −727.6% | 0.0× | 0.92 |
| Median of the others | US$503.5M | US$316.2M | 23.3× | 2.2× | −503.7% | 0.0× | 1.64 |
Forecasts
8 strong buy · 1 buy · 1 hold · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 30.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -3.29 · 2 analysts
- Revenue, year to Dec 2026
- 6.91M · 7 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Martin Babler | President, Chief Executive Officer and Chairman of the Board |
| John Schroer | Chief Financial Officer |
| Sanam Pangali | Chief Legal Officer and Corporate Secretary |
| Claire Langrish | SVP, Head of Immunology and Translational Science |
| Grace Halteh | SVP, Head of Quality and Regulatory |
| Kolbot By | SVP, Head of Technical Operations |
| Alan B. Colowick | Managing Director, AyurMaya, an affiliate of Matrix Capital Management |
| David M Goldstein | Chief Scientific Officer |
| Jack Danilkowicz | Chief Commercial Officer |
| Jörn Drappa | Chief Medical Officer |
| Mark Bradley | Chief Development Officer |
| Roy Hardiman | Chief Business and Strategy Officer |
| Srinivas Akkaraju | Founder and Managing Member, Samsara BioCapital |
Board
| Director | Role |
|---|---|
| Martin Babler | President, Chief Executive Officer and Chairman of the Board |
| James B. Tananbaum | Director |
| Lynn Tetrault | Independent Board Member |
| Patrick Machado | Independent Board Member |
| Sapna Srivastava | Independent Board Member |
| Srinivas Akkaraju | Founder and Managing Member, Samsara BioCapital |
| Zhengbin Yao | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 12, 2026 · After close | −8.7% |
| Q2 2026 | Aug 13, 2026 · After close | +3.7% |
| Q1 2026 | May 14, 2026 · After close | −7.2% |
| Q4 2025 | Mar 19, 2026 · After close | −1.3% |
| Q3 2025 | Nov 13, 2025 · After close | +4.5% |
| Q2 2025 | Aug 13, 2025 · After close | −0.7% |
| Q1 2025 | May 14, 2025 · After close | +18.6% |
| Q4 2024 | Mar 19, 2025 | −20.3% |
| Q3 2024 | Nov 13, 2024 · After close | −12.9% |
| Q2 2024 | Aug 13, 2024 · After close | +1.4% |
All 11 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 29, 2024 |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Technical Presentation (September 2026) | Technical | 20 slides | Sep 1, 2026 |
| Investor Presentation (August 2026) | Investor deck | 37 slides | August 2026 |
| Investor Presentation (June 2026) | Investor deck | 36 slides | Jun 29, 2026 |
| Technical Presentation (May 2026) | Technical | 21 slides | May 14, 2026 |
| Envudeucitinib ONWARD1 and ONWARD2 Phase 3 Topline Readout Analyst and Investor Webcast (January 2026) | Conference | 25 slides | Jan 6, 2026 |
| Corporate Update (January 2026) | Corporate update | 25 slides | Jan 6, 2026 |
| Investor Presentation (2026) | Investor deck | 39 slides | 2026 |
| ASOPRS 2025 | Conference | 14 slides | Sep 26, 2025 |
| Investor Presentation (September 2025) | Investor deck | 45 slides | Sep 3, 2025 |
| Jefferies Global Healthcare Conference 2025 | Conference | 27 slides | June 2025 |
All 18 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Merger or Acquisition (March 2025) | Merger or acquisition | 10 slides | Mar 18, 2025 |
| Technical Presentation (March 2025) | Technical | 14 slides | Mar 10, 2025 |
| Merger or Acquisition (February 2025) | Merger or acquisition | 18 slides | Feb 6, 2025 |
| European Academy of Dermatology and Venereology (EADV) Congress 2024 | Conference | 12 slides | September 2024 |
| Technical Presentation (September 2024) | Technical | 14 slides | September 2024 |
| ESOPRS 2024 | Conference | 14 slides | September 2024 |
| Technical Presentation (May 2024) | Technical | 14 slides | May 31, 2024 |
| Technical Presentation (March 2024) | Technical | 16 slides | March 2024 |
Financings
| Raise | Date |
|---|---|
| Public offering of common stock Closed: US$345.1M raised · US$17 a share · Morgan Stanley +5 Dealers: Morgan Stanley (lead), Leerink Partners (lead), Cantor (lead), Wells Fargo Securities (lead), Baird (co-lead), Oppenheimer & Co. (co-lead) | Jan 9, 2026 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$16.00 a share on Jun 27, 2024.
- Price
- US$16.00 a share
- Shares offered
- 13,125,000 shares of common stock
- Offering size
- US$210 million
- Underwriters' option
- Up to 1,968,750 more shares
- Listing
- ALMS on the Nasdaq Global Select Market
- Underwriters
- Morgan Stanley, Leerink Partners, Cantor, Guggenheim Securities · In the order on the cover
- Shares delivered
- On or about Jul 1, 2024
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Apr 11, 2024 |
| Filed publicly | Jun 7, 2024 |
| Amended twice | Newest Jun 24, 2024 |
| Shares registered with an exchange | Jun 25, 2024 |
| Declared effective by the SEC | Jun 27, 2024 |
| Final prospectus, with the price | Jun 28, 2024 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Jun 28, 2024 |
| FWP · Free writing prospectus | Jun 28, 2024 |
| EFFECT · Notice that a registration is effective | Jun 27, 2024 |
| CERT · Exchange's certificate of listing | Jun 27, 2024 |
| 8-A12B · Registration of shares for listing on an exchange | Jun 25, 2024 |
| CORRESP · Letter to the SEC | Jun 25, 2024 |
| CORRESP · Letter to the SEC | Jun 25, 2024 |
| S-1/A · Registration statement, amended | Jun 24, 2024 |
| CORRESP · Letter to the SEC | Jun 18, 2024 |
| S-1/A · Registration statement, amended | Jun 18, 2024 |
All 19 filings
| Filing | Filed |
|---|---|
| UPLOAD · Letter from the SEC | Jun 17, 2024 |
| CORRESP · Letter to the SEC | Jun 14, 2024 |
| CORRESP · Letter to the SEC | Jun 7, 2024 |
| S-1 · Registration statement | Jun 7, 2024 |
| UPLOAD · Letter from the SEC | May 30, 2024 |
| DRSLTR · Letter to the SEC with a draft | May 15, 2024 |
| DRS/A · Draft registration statement, amended | May 15, 2024 |
| UPLOAD · Letter from the SEC | May 8, 2024 |
| DRS · Draft registration statement | Apr 11, 2024 |
Open IPO · From the cover of the final prospectus (424B4) filed Jun 28, 2024
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | 24.1M | 0 | 0 | 0 |
| Cost of revenue | 3.50M | 3.15M | 1.28M | 250.0K |
| Gross profit | 20.6M | -3.15M | -1.28M | -250.0K |
| Research and development | 386.0M | 265.6M | 137.7M | 101.1M |
| Selling, general and administrative | 91.9M | 35.2M | 20.5M | 12.5M |
| Operating income | -453.8M | -300.8M | -158.2M | -113.8M |
| Depreciation and amortization | 3.50M | 3.15M | 1.28M | 250.0K |
| EBITDA | -450.3M | -297.6M | -156.9M | -113.6M |
| Income before tax | -251.9M | -294.2M | -155.0M | -111.9M |
| Income tax | -8.56M | 0 | 0 | |
| Net income | -243.3M | -294.2M | -155.0M | -111.9M |
| Earnings per share, basic | -2.86 | -10.38 | -72.08 | -14.93 |
| Earnings per share, diluted | -2.86 | -10.38 | -72.08 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash and equivalents | 89.7M | 169.5M | 46.0M | 25.6M |
| Short-term investments | 218.8M | 118.7M | 2.96M | 67.3M |
| Receivables | 2.08M | 1.81M | 722.0K | 500.0K |
| Inventory | -95.0K | |||
| Current assets | 318.2M | 306.2M | 53.4M | 102.6M |
| Property, plant and equipment | 18.2M | 21.0M | 22.4M | |
| Total assets | 411.9M | 341.0M | 89.6M | 108.2M |
| Accounts payable | 10.1M | 9.62M | 1.12M | 1.72M |
| Current liabilities | 73.3M | 50.9M | 20.9M | 13.4M |
| Total debt | 36.9M | 30.7M | 32.6M | 1.78M |
| Total liabilities | 110.6M | 80.9M | 53.5M | 303.4M |
| Shareholders' equity | 301.3M | 260.1M | -339.3M | -195.2M |
| Shares outstanding | 850.3M | 28.3M | 51.8M | 7.50M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash from operations | -369.5M | -255.1M | -130.0M | -107.7M |
| Capital spending | -653.0K | -1.73M | -4.50M | -2.41M |
| Free cash flow | -370.2M | -256.8M | -134.5M | -110.1M |
| Cash from investing | 287.9M | -113.8M | 60.5M | -68.8M |
| Cash from financing | 2.07M | 492.4M | 89.7M | 101.6M |
| Share buybacks | -17.0K | -6.00K | -64.0K | |
| Change in cash | -79.6M | 123.5M | 20.2M | -74.8M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 5, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 9, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Sep 1, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Aug 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 13, 2026 | Results | SEC |
| 8-K · Current report | Aug 10, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 6, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 5, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 27, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 8, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 6, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jul 2, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jul 2, 2026 | Meeting outcome | SEC |
| 8-K · Current report | Jun 29, 2026 | Current report | SEC |
| 4 · Change in ownership | May 27, 2026 | Insider trade | SEC |
| ARS · Annual report to shareholders | May 18, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | May 18, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | May 18, 2026 | Meeting notice | SEC |
| 10-Q · Quarterly report | May 14, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 7, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 3, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Apr 3, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Mar 30, 2026 | Current report | SEC |
| S-3ASR · Registration statement | Mar 19, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 19, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 19, 2026 | Results | SEC |
| 5 · Annual statement of ownership | Feb 11, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Jan 30, 2026 | Offer document | SEC |
| 4 · Change in ownership | Jan 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jan 13, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jan 12, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 12, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 9, 2026 | Results | SEC |
| 424B5 · Prospectus | Jan 8, 2026 | Offer document | SEC |
| 424B5 · Prospectus | Jan 6, 2026 | Offer document | SEC |
| 8-K · Current report | Jan 6, 2026 | Current report | SEC |
| 8-K · Current report | Jan 2, 2026 | Current report | SEC |
| 4 · Change in ownership | Dec 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 25, 2025 | Insider trade | SEC |
| SCHEDULE 13D · Big-stake notice | Nov 24, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 17, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Nov 17, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 17, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 13, 2025 | Results | SEC |
| 8-K · Current report | Sep 3, 2025 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Aug 20, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Aug 15, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 13, 2025 | Results | SEC |
| 8-K · Current report | Aug 4, 2025 | Meeting outcome | SEC |
| 4 · Change in ownership | Aug 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 31, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 31, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 31, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 31, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 31, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 31, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 31, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 31, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 14, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 14, 2025 | Insider trade | SEC |
| UPLOAD · Letter from the SEC | Jul 9, 2025 | Other filings | SEC |
| S-3 · Registration statement | Jul 3, 2025 | Offer document | SEC |
| 8-K/A · Current report, amended | Jun 30, 2025 | Current report | SEC |
| ARS · Annual report to shareholders | Jun 16, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Jun 16, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Jun 16, 2025 | Meeting notice | SEC |
| S-8 · Registration statement for employee plans | Jun 10, 2025 | Offer document | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jun 10, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | May 23, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | May 23, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | May 23, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 23, 2025 | Insider trade | SEC |
| 8-K · Current report | May 21, 2025 | Acquisition or disposal | SEC |
| 8-K · Current report | May 19, 2025 | Meeting outcome | SEC |
| 10-Q · Quarterly report | May 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2025 | Results | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | May 7, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | May 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 6, 2025 | Insider trade | SEC |
| 425 | Apr 29, 2025 | Other filings | SEC |
| EFFECT · Notice that a registration is effective | Apr 24, 2025 | Other filings | SEC |
| 424B3 · Prospectus | Apr 23, 2025 | Offer document | SEC |
| 10-K/A · Annual report, amended | Apr 23, 2025 | Annual report | SEC |
| CORRESP · Letter to the SEC | Apr 22, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Apr 22, 2025 | Other filings | SEC |
| S-4 · Registration statement | Apr 21, 2025 | Offer document | SEC |
| 425 | Apr 21, 2025 | Other filings | SEC |
| 425 | Apr 21, 2025 | Other filings | SEC |
| 425 | Apr 21, 2025 | Other filings | SEC |
| 8-K · Current report | Apr 21, 2025 | Material contract | SEC |
| EFFECT · Notice that a registration is effective | Apr 7, 2025 | Other filings | SEC |
| 425 | Apr 4, 2025 | Other filings | SEC |
| 424B3 · Prospectus | Apr 4, 2025 | Offer document | SEC |
| 4 · Change in ownership | Apr 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 3, 2025 | Insider trade | SEC |
| CORRESP · Letter to the SEC | Apr 2, 2025 | Other filings | SEC |
| S-4/A · Registration statement, amended | Apr 2, 2025 | Offer document | SEC |
| S-4 · Registration statement | Mar 27, 2025 | Offer document | SEC |
| 425 | Mar 25, 2025 | Other filings | SEC |
| 8-K · Current report | Mar 25, 2025 | Current report | SEC |
| S-8 · Registration statement for employee plans | Mar 19, 2025 | Offer document | SEC |
| 425 | Mar 19, 2025 | Other filings | SEC |
| 10-K · Annual report | Mar 19, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 19, 2025 | Results | SEC |
| 8-K · Current report | Mar 18, 2025 | Current report | SEC |
| 425 | Mar 18, 2025 | Other filings | SEC |
| 425 | Mar 11, 2025 | Other filings | SEC |
| 8-K · Current report | Mar 10, 2025 | Current report | SEC |
| 425 | Mar 6, 2025 | Other filings | SEC |
| 425 | Mar 4, 2025 | Other filings | SEC |
| 8-K · Current report | Mar 4, 2025 | Current report | SEC |
| 8-K · Current report | Feb 21, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Feb 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2025 | Insider trade | SEC |
| UPLOAD · Letter from the SEC | Feb 19, 2025 | Other filings | SEC |
| DRS · Draft registration statement | Feb 14, 2025 | Offer document | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Feb 10, 2025 | Big-stake notice | SEC |
| 425 | Feb 7, 2025 | Other filings | SEC |
| 425 | Feb 6, 2025 | Other filings | SEC |
| 425 | Feb 6, 2025 | Other filings | SEC |
| 425 | Feb 6, 2025 | Other filings | SEC |
| 8-K · Current report | Feb 6, 2025 | Results | SEC |
| UPLOAD · Letter from the SEC | Dec 3, 2024 | Other filings | SEC |
| 8-K · Current report | Nov 25, 2024 | Current report | SEC |
| 10-Q · Quarterly report | Nov 13, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 13, 2024 | Results | SEC |
| SC 13D · Big-stake notice | Aug 27, 2024 | Big-stake notice | SEC |
| 4/A · Change in ownership, amended | Aug 27, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 13, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 13, 2024 | Results | SEC |
| D | Jul 24, 2024 | Other filings | SEC |
| 8-K · Current report | Jul 18, 2024 | Current report | SEC |
| SC 13G · Big-stake notice | Jul 11, 2024 | Big-stake notice | SEC |
| SC 13D · Big-stake notice | Jul 5, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 3, 2024 | Insider trade | SEC |
| SC 13D · Big-stake notice | Jul 3, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 3, 2024 | Insider trade | SEC |
| 8-K · Current report | Jul 3, 2024 | Material contract | SEC |
| SEC STAFF LETTER | Jul 2, 2024 | Other filings | SEC |
| 4 · Change in ownership | Jul 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2024 | Insider trade | SEC |
This page holds 200 of 250 filings. Open Filings
Cap table
Built by 6ix from Alumis Inc.’s releases · as of Jan 9, 2026
- Common shares
- 129,435,239
- Fully diluted
- 129,435,239
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 129,435,239 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 129,435,239 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Patrick Machado Other companies: Xenon Pharmaceuticals Inc. (Director · Since at least Nov 5, 2020); Arcus Biosciences, Inc. (Board Member · Since at least Dec 10, 2019); Adverum Biotechnologies Inc (Director · Since at least Mar 14, 2017); Turnstone Biologics Corp. (Director · Jul 20, 2023 – Jul 20, 2023 · Past); Acelyrin, Inc. (Director · May 4, 2023 – May 21, 2025 · Past); Roivant Sciences Ltd. (Director · Oct 1, 2021 – Oct 1, 2021 · Past); Principia Biopharma Inc (Director · Jun 11, 2019 – Sep 28, 2020 · Past); Turning Point Therapeutics Inc (Director · May 13, 2019 – Aug 17, 2022 · Past); Endocyte Inc (Director · Feb 27, 2018 – Dec 21, 2018 · Past); Sio Gene Therapies Inc (Director · Jul 17, 2017 – Jul 17, 2017 · Past); Rocket Pharmaceuticals, Inc. (Director · Aug 17, 2016 – Jun 20, 2017 · Past); Scynexis, Inc. (Director · Sep 24, 2015 – Jan 2, 2019 · Past); Chimerix Inc (Director · Jun 20, 2014 – Jun 9, 2023 · Past); Medivation Inc (Director · Jun 5, 2007 – Sep 28, 2016 · Past) | Independent Board Member · Since at least Jun 27, 2024 |
| Srinivas Akkaraju Other companies: Kalaris Therapeutics, Inc. (Director · Since at least Mar 18, 2025); vTv Therapeutics Inc. (Director · Since at least Feb 23, 2024); Mineralys Therapeutics, Inc. (Board Member · Since at least Feb 9, 2023); Scholar Rock Holding Corporation (Director · Since at least Jul 26, 2022); Jiya Acquisition Corp (Director · Sep 23, 2022 – Sep 23, 2022 · Past); Syros Pharmaceuticals, Inc. (Director · Jun 1, 2022 – Sep 16, 2024 · Past); Aduro Biotech Inc (Director · May 26, 2022 – Aug 11, 2023 · Past); Intercept Pharmaceuticals Inc (Director · May 25, 2022 – Nov 8, 2023 · Past) | Founder and Managing Member, Samsara BioCapital · Since at least Jun 27, 2024 |
| David E Goel Other companies: Acelyrin, Inc. (Director · May 4, 2023 – May 21, 2025 · Past); Zentalis Pharmaceuticals, Inc. (Director · Apr 3, 2020 – Apr 3, 2020 · Past); Adaptive Biotechnologies Corporation (Director · Jun 26, 2019 – Feb 15, 2021 · Past); Popular, Inc. (Director · Feb 12, 2012 – May 8, 2018 · Past) | Director · Jun 27, 2024 – May 21, 2025 · Past |
| Martin Babler Other companies: MapLight Therapeutics, Inc. (Member of the Audit Committee · Since at least Jun 23, 2026); 89bio Inc (Director · Since at least Apr 13, 2024); Prelude Therapeutics Incorporated (Director · Since at least Jun 17, 2022); Neurogene Inc. (Director · May 12, 2022 – Jun 8, 2023 · Past) | President, CEO and Chairman, Director · Since at least Jun 27, 2024 |
| Lynn A. Tetrault Other companies: NeoGenomics, Inc. (Director · Since at least Jun 2, 2021); Rhythm Pharmaceuticals, Inc. (Director · Since at least Dec 9, 2020); Acelyrin, Inc. (Director · Dec 18, 2023 – May 21, 2025 · Past) | Director · Since at least May 21, 2025 |
| Sapna Srivastava Other companies: Nuvalent, Inc. (Director · Since at least Jun 18, 2025); Aura Biosciences, Inc. (Director · Since at least Jun 17, 2025); Tourmaline Bio Inc. (Director · Since at least Jun 4, 2025) | Director · Since at least Jul 30, 2025 |
| Jim Tananbaum Other companies: Latigo Biotherapeutics, Inc. (Director · Since at least Aug 10, 2026) | Director · Since at least Apr 1, 2026 |
| Sanam Pangali Other companies: Acelyrin, Inc. (CLO & Head of People · May 9, 2024 – May 23, 2024 · Past) | Chief Legal Officer · Since at least Jul 4, 2025 |
| Alan B. Colowick | Managing Director, AyurMaya, an affiliate of Matrix Capital Management · Since at least Nov 5, 2026 |
| Claire Langrish | SVP, Head of Immunology and Translational Science · Since at least Nov 4, 2026 |
All 19 people
| Person | Seat |
|---|---|
| David M Goldstein | Chief Scientific Officer · Since at least Nov 4, 2026 |
| Grace Halteh | SVP, Head of Quality and Regulatory · Since at least Nov 4, 2026 |
| Jack Danilkowicz | Chief Commercial Officer · Since at least Jan 28, 2025 |
| John Schroer | Chief Financial Officer · Since at least Aug 3, 2026 |
| Jörn Drappa | Chief Medical Officer · Since at least May 22, 2026 |
| Kolbot By | SVP, Head of Technical Operations · Since at least Nov 4, 2026 |
| Mark Bradley | Chief Development Officer · Since at least Jul 29, 2025 |
| Roy Hardiman | Chief Business and Strategy Officer · Since at least Jan 28, 2025 |
| Zhengbin Yao | Director · Since at least Jul 2, 2026 |
Log in to ask 6ix AI your own questions about Alumis Inc.